Onco-Summaries: Daily Oncology Updates at a Glance

31/07/2025

MaxCyte and Anocca AB signed a Strategic Platform Licensing Agreement to advance TCR-T cell therapies (Ref)

MaxCyte signed a Strategic Platform License Agreement (SPL) with Anocca AB in which Anocca AB will deploy MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support the scalable development and manufacturing of its TCR-T cell therapy pipeline.

• Anocca AB obtained non-exclusive research, clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform

  
  

• MaxCyte is entitled to receive annual licensing fees and program-related revenue